CymaBay Therapeutics Inc.’s Phase IIb setback in non-alcoholic steatohepatitis (NASH) battered its stock price on 11 June and had a carryover effect for Genfit SA, which is in Phase III in NASH in the same drug class.
However, CymaBay is trying to shift the narrative on its drug seladelpar, pointing out that the PPAR delta agonist yielded notable liver biomarker improvements in the study, suggesting that
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?